Study type: In vivo/preclinical · Status: Verified against declared source
New insight for SS‑31 in treating diabetic cardiomyopathy: Activation of mitoGPX4 and alleviation of mitochondria‑dependent ferroptosis.
International journal of molecular medicine · 2024
Study scale: Prior to the experiment, the mice were acclimated for 1 week.
Abstract only: Open source record
Product or molecular entity relationships
- SS-31: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
SS-31 is a mitochondria-targeting antioxidant that exhibits promising therapeutic potential for various diseases; however, its protective effect on diabetic cardiomyopathy (DCM) remains to be elucidated.
Methods
Total RNA from cells on 6-well plate or 50 mg tissue was extracted by RNAiso Plus reagent (cat.
Scale or participants
Prior to the experiment, the mice were acclimated for 1 week.
Key findings
SS-31 is a mitochondria-targeting antioxidant that exhibits promising therapeutic potential for various diseases; however, its protective effect on diabetic cardiomyopathy (DCM) remains to be elucidated.
Limitations and uncertainty
SS-31 is a mitochondria-targeting antioxidant that exhibits promising therapeutic potential for various diseases; however, its protective effect on diabetic cardiomyopathy (DCM) remains to be elucidated.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.